A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer (Q48031013)

From Wikidata

Jump to navigation Jump to search

scientific article published in May 2012

edit

Language	Label	Description	Also known as
English	A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer	scientific article published in May 2012

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22409262

retrieved

7 February 2018

reference URL

http://europepmc.org/abstract/MED/22409262

title

A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22409262

retrieved

7 February 2018

reference URL

http://europepmc.org/abstract/MED/22409262

main subject

phase II clinical trial

0 references

patient

0 references

thromboembolism

1 reference

based on heuristic

inferred from title

apixaban

1 reference

based on heuristic

inferred from title

author name string

M N Levine

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22409262

retrieved

7 February 2018

reference URL

http://europepmc.org/abstract/MED/22409262

C Gu

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22409262

retrieved

7 February 2018

reference URL

http://europepmc.org/abstract/MED/22409262

H A Liebman

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22409262

retrieved

7 February 2018

reference URL

http://europepmc.org/abstract/MED/22409262

C P Escalante

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22409262

retrieved

7 February 2018

reference URL

http://europepmc.org/abstract/MED/22409262

S Solymoss

series ordinal

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22409262

retrieved

7 February 2018

reference URL

http://europepmc.org/abstract/MED/22409262

D Deitchman

series ordinal

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22409262

retrieved

7 February 2018

reference URL

http://europepmc.org/abstract/MED/22409262

L Ramirez

series ordinal

7

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22409262

retrieved

7 February 2018

reference URL

http://europepmc.org/abstract/MED/22409262

J Julian

series ordinal

8

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22409262

retrieved

7 February 2018

reference URL

http://europepmc.org/abstract/MED/22409262

publication date

1 May 2012

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22409262

retrieved

7 February 2018

reference URL

http://europepmc.org/abstract/MED/22409262

published in

Journal of Thrombosis and Haemostasis

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22409262

retrieved

7 February 2018

reference URL

http://europepmc.org/abstract/MED/22409262

volume

10

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22409262

retrieved

7 February 2018

reference URL

http://europepmc.org/abstract/MED/22409262

issue

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22409262

retrieved

7 February 2018

reference URL

http://europepmc.org/abstract/MED/22409262

page(s)

807-814

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22409262

retrieved

7 February 2018

reference URL

http://europepmc.org/abstract/MED/22409262

cites work

Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04693.X

retrieved

21 January 2018

PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04693.X

retrieved

21 January 2018

Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04693.X

retrieved

21 January 2018

Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04693.X

retrieved

21 January 2018

American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04693.X

retrieved

21 January 2018

The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04693.X

retrieved

21 January 2018

Apixaban or enoxaparin for thromboprophylaxis after knee replacement

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04693.X

retrieved

21 January 2018

Apixaban versus enoxaparin for thromboprophylaxis after hip replacement

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04693.X

retrieved

21 January 2018

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04693.X

retrieved

21 January 2018

Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04693.X

retrieved

21 January 2018

New Anticoagulants

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04693.X

retrieved

21 January 2018

Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2012.04693.X

retrieved

21 January 2018

Identifiers

DOI

10.1111/J.1538-7836.2012.04693.X

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22409262

retrieved

7 February 2018

reference URL

http://europepmc.org/abstract/MED/22409262

PubMed publication ID

22409262

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22409262

retrieved

7 February 2018

reference URL

http://europepmc.org/abstract/MED/22409262

ResearchGate publication ID

221695145

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48031013&oldid=2181975516"